Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Severe Renal Impairment and With End-stage Renal Disease

NCT06814132 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT06814132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06814132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Severe Renal Impairment and With End-stage Renal Disease
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Completed
Start date
April 7, 2025
Completion date
October 14, 2025
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage kidney disease, healthy participants, kidney failure, chronic, renal failure, chronic, renal failure, end-stage